SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys strong quarterly results and raised outlook have been overshadowed by a sharp selloff, with traders focused on negative cash flow, heavy spending to expand production, and valuation after the stocks run-up. Bulls call the decline an overreaction and point to demand for data-center power, while bears question whether growth will translate into cash generation.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics early Phase 1 azer-cel results in progressive MS are driving attention, with traders highlighting encouraging safety and signs of disability stability or improvement as a potential pipeline opportunity beyond BRIUMVI. Others say the stock reaction has been underwhelming and caution that the findings come from a small, uncontrolled study; BRIUMVIs subcutaneous trial data and earnings are also in focus.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Anticipation of Anthropics potential IPO and related S-1 filing is driving attention, with traders viewing DXYZ as a public-market proxy for its private-company holdings and debating whether those holdings support a higher NAV. Bullish excitement over a possible IPO-fueled rerating is tempered by concerns about delays, weak price action, and the gap between estimated NAV and the share price.

Icahn Enterprises LP is a holding company. It operates through the following segments: Investment, Automotive, Energy, Food Packaging, Real Estate, Home Fashion, Pharma, and Holding Company. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group, LLC. The Energy segment refers to petroleum refining and marketing businesses. The Food Packaging segment involves the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Real Estate segment offers rental real estate, property development, and resort activities. The Home Fashion segment deals with manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operate through Vivus, Inc., a specialized pharmaceutical company. The Holding Company segment manages acquisition and investment in operating businesses. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

IEPs steep decline has traders focused on whether its high distribution is sustainable, with speculation about a cut and concern over hedging losses, debt maturities, and upcoming earnings. Some see value in IEPs CVR Energy stake and potential short-squeeze dynamics, while others argue that continued losses and dilution outweigh the distribution.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

BDR Pharmaceuticals lawsuit challenging the FDAs refusal to accept a generic application for VOQUEZNA has raised concerns that Phathoms exclusivity could be shortened, weighing on shares. Traders debate how serious the risk is: some see a long-term overhang, while others stress the suit is not approval of a generic and expect the FDAs exclusivity decision to stand.

American Express Co. engages in the provision of card-issuing, merchant-acquiring, and card network businesses. Its products and services include credit cards, business credit cards, corporate programs, gift cards, savings accounts and CDs, and the American Express App. It operates through the following segments: the United States Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS), Global Merchant and Network Services (GMNS), and Corporate and Other. The USCS segment includes proprietary consumer cards and provides services to United States consumers. The CS segment offers corporate and small business cards and provides services to United States businesses. The ICS segment provides consumers, small businesses, and corporate cards outside the United States. The GMNS segment is involved in operating a global payments network that processes and settles card transactions, acquires merchants, and provides multi-channel marketing programs and capabilities, services and data analytics. The Corporate and Other segment covers corporate functions and certain other businesses and operations. It also operates through the following geographical segments: United States, EMEA, APAC, LACC, and Other. The EMEA segment represents Europe, the Middle East, and Africa. The APAC segment refers to Asia Pacific, Australia, and New Zealand. The LACC segment focuses on Latin America, Canada, and the Caribbean. The Other segment includes net costs which are not directly allocated to specific geographic regions. The company was founded by Henry Wells, William G. Fargo, and John Warren Butterfield on March 28, 1850 and is headquartered in New York, NY.

American Express Co.

American Express shares are drawing attention after quarterly results beat profit expectations and the company raised its earnings outlook, but revenue fell slightly short and plans to cut about 5% of its global workforce as part of a restructuring. Traders are divided: some see the selloff as excessive given the stronger guidance, while others focus on the revenue miss, layoffs, and consumer-spending concerns.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs steep decline toward fresh lows is driving a largely bearish discussion, with traders tying the pressure to doubts about the companys value and dilution as well as Trump-linked political and Iran-war headlines. Some point to a possible technical floor or bounce, but the dominant tone is skepticism about the stocks prospects.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martins quarterly earnings beat, raised outlook, record backlog and 10-year F-35 framework for 850 aircraft are driving attention, reinforcing the defense-demand growth story. Traders are largely bullish on the move, though some warn the sharp rally may be overbought and vulnerable to a pullback.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

A sharp gold selloff has put GLDs safe-haven role under scrutiny, with traders pointing to dollar and rate concerns and its recent tendency to fall alongside risk assets; others see the pullback near support as a buying opportunity.

Bitdeer Technologies Group engages in the cryptocurrency mining industry. It generates income through its proprietary mining datacenters. The firm handles complex processes involved in computing such as equipment procurement, transport logistics, datacenter design and construction, equipment management, and daily operations. The company was founded by Wu Jihan in December 2021 and is headquartered in Singapore.

Bitdeer Technologies Group. - Ordinary Shares - Class A

Bitdeer Technologies Holding Co

BTDR is drawing attention for a steep selloff and persistent underperformance versus other bitcoin miners, even as traders point to its bitcoin production growth and AI/data-center contracts. The community debates whether dilution concerns, heavy short interest, or broader weakness in crypto and AI infrastructure stocks are weighing on shares, while some investors view the decline as a buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLSPR NewswireNEW YORK, Oct. 22, 2026 NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLSPR NewswireNEW YORK, Oct. 15, 2026NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLSPR NewswireNEW YORK, Oct. 8, 2026NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLSPR NewswireNEW YORK, Sept. 24, 2026 NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is...

CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cellectis S.A. (Cellectis or the Company) (NASDAQ: CLLS) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on...

Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cellectis S.A. (Cellectis or the Company) (NASDAQ: CLLS) investors concerning the Companys possible violations of the federal securities laws. IF...

Cellectis S.A. (CLLS) Shareholders Who Lost Money Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of Cellectis S.A. (Cellectis or the Company) (NASDAQ: CLLS) investors concerning the Companys possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CELLECTIS S.A. (CLLS), CONTACT THE LAW...

Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Cellectis S.A. (Cellectis or the Company) (NASDAQ: CLLS) on behalf of investors concerning the Companys possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON CELLECTIS S.A. (CLLS), CLICK HERE TO INQUIRE...

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Analysts downgraded Banco Santander Brasil, Ribbon Communications, Cellectis, Scholar Rock, with mixed price-target changes.read more...

CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot

Equity

Cellectis received a downgrade after pivoting to cardiovascular diseases therapy from a type of cancer therapy


Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

Cellectis - ADR

Bullish Sentiment

<ul class="summary-bullets"><li>Citizens downgraded Cellectis to ‘Market Perform’ from ‘Outperform’ without a price target.</li><li>Cellectis is stopping the development of Lasme-cel and Eti-cel, two allogeneic CAR-T treatments being studied for blood cancers.</li><li>The company will continue existing cell-therapy partnerships with AstraZeneca, Allogene Therapeutics, Servier and Iovance Biotherapeutics</li></ul>Cellectis (CLLS) remained on investors’ radar on Tuesday as the biotech firm received a downgrade from Citizens after it stopped further development of its lead blood-cancer treatments and shifted its focus toward cardiovascular diseases.Citizens downgraded Cellectis to ‘Market Perform’ from ‘Outperform’ without a price target. The firm said the strategy change pushes the company’s major clinical catalysts out to late 2027 and 2028, and it now views the shares as fairly valued.<a href="https://stocktwits.com/symbol/CLLS">CLLS shares</a> were down more than 14% in pre-market trading and are on track to slump to their lowest levels since July 2025. CLLS stock crashed more than 40% in the previous session.<h2 class="st-heading-2">Why Is Cellectis Pivoting?</h2>Cellectis is stopping the development of Lasme-cel and Eti-cel, two allogeneic CAR-T treatments being studied for blood cancers. Allogeneic CAR-T treatments use immune cells from healthy donors that are genetically modified to attack cancer.The company said improvements in existing cancer treatments have reduced the number of patients reaching later stages of therapy, while growing competition from bispecific antibodies and newer in-vivo CAR-T approaches has made the market less attractive.Cellectis will instead focus on using its gene-editing technology directly inside a patient’s body, initially targeting cardiovascular risk factors.<h2 class="st-heading-2">No Changes To Existing Partnerships With AZN, ALLO, IOVA</h2>Cellectis said the restructuring should extend its cash runway into the second half of 2028. It will also continue existing cell-therapy partnerships with&nbsp;<a href="https://stocktwits.com/symbol/AZN">AstraZeneca (AZN)</a>, Allogene Therapeutics, Servier and&nbsp;<a href="https://stocktwits.com/symbol/IOVA">Iovance Biotherapeutics (IOVA)</a>.The company’s lead program, HEAL-101, is designed to lower very high levels of triglycerides, a type of fat in the blood that can increase the risk of heart disease and other serious health problems. Early Phase 1 data are expected in the second half of 2027.Its second program, HEAL-201, is designed to lower lipoprotein cholesterol, or ‘bad’ cholesterol, which can contribute to heart disease. Early Phase 1 results are expected in the first half of 2028.<h2 class="st-heading-2">Retail ‘Extremely Bullish’ Despite Sharp Selloff</h2>Despite the massive sell-off, retail sentiment surrounding CLLS on Stocktwits turned ‘extremely bullish’ from ‘bullish’ over the past 24 hours.CLLS shares have crashed more than 62% so far this year, underperforming partner IOVA’s 267% surge,&nbsp;<a href="https://stocktwits.com/symbol/ALLO">ALLO’s</a> 31% gains and AZN’s 10% losses.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/ai-fed-5-treasury-yield-three-risks-putting-nasdaq-dow-futures-on-edge-ahead-of-wednesday-rate-decision/cZtnPK2RBTu">&nbsp;AI, Fed And 5% Treasury Yield: Three Risks Putting Nasdaq, Dow Futures On Edge Ahead Of Wednesday’s Rate Decision</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Cellectis logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Cellectis received a downgrade after pivoting to cardiovascular diseases therapy from a type of cancer therapy

CLLS Stock Slides Toward 14-Month Low: Citizens Downgrades Cellectis After Cancer Pipeline Pivot 

Allogene Therapeutics Inc

AstraZeneca PLC

Cellectis

Iovance Biotherapeutics Inc

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.9794
Prev Close	$0.975
Open	$1.00
Dividend Yield	0.00%
50-Day Moving Average	$2.14
Beta	1.25
Avg. Volume	192,264.09
PE Ratio	-1.50

52-Week High	$5.45
52-Week Low	$0.8808
Market Capitalization	$70.52M
EPS (Annual)	-$0.6761
Price to Book	2.39
Revenue Per Employee	$319,540.26

Feed

News

Sentiment

Earnings

Fundamentals

Info

CLLS Fundamentals